Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...

Conductor Daniel Barenboim says he has been diagnosed with Parkinson's disease. The 82-year-old issued a statement Thursday ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

Daniel Barenboim, the eminent conductor and pianist who stepped back from engagements in recent years citing health concerns, ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Sharon Osbourne gave an update on how Parkinson’s disease has impacted husband Ozzy Osbourne’s legs as the musician prepares ...

The renowned musician says he plans to keep playing, after confirming the long-suspected diagnosis.

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...